DBV Technologies is a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Viaskin™. Co.'s therapeutic approach is based on epicutaneous immunotherapy, or EPIT™, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin™. Co.'s lead product candidate, Viaskin™ Peanut, has completed a global Phase III program for the treatment of peanut-allergic patients four to 11 years of age. Co.'s second product candidate, Viaskin™ Milk, is in development for the treatment of cow's milk protein allergy children two to 17 years of age.